InvestSMART

AFT Pharmaceuticals Limited (ASX:AFP)

ALERT: Price-sensitive ASX Announcement for AFP
Current share price for AFP : $3.290 0.43 (15.03%)+
Announcement
Release
21 May 2026 7:30AM
Price at Release
$2.860
Full Release
download
Summary
AFT Pharmaceuticals Limited reported a significant year of growth in FY26 with total sales reaching $254.7 million, marking a 22% increase from the previous year. The company achieved an operating profit of $24.4 million, surpassing prior guidance. Revenue growth was driven by strong sales across all territories, including a 19% increase in Australia, 66% internationally, and 41% in Asia. AFT's strategy focuses on expanding its global footprint, supported by a robust pipeline of 8 patented R&D products and a number of licensing agreements. The company aims for a $300 million revenue target in FY27, emphasizing continued expansion in Australasian markets, international launches, and R&D advancements.
Key Points
  • Total sales in FY26 were $254.7 million, a 22% increase from FY25.
  • Operating profit in FY26 was $24.4 million.
  • Australia remains the largest market with a 19% revenue growth.
  • International revenue increased by 66%, and Asia saw a 41% growth.
  • Company aims for $300 million revenue target in FY27.
  • Significant R&D investments with 8 patented products in pipeline.
  • Expansion into 87 countries with ongoing licensing agreements.
  • Focus on Australasian markets, international launches, and R&D.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.